Article | Published:

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Nature Chemical Biology volume 4, pages 691699 (2008) | Download Citation

Subjects

Abstract

The clinical success of multitargeted kinase inhibitors has stimulated efforts to identify promiscuous drugs with optimal selectivity profiles. It remains unclear to what extent such drugs can be rationally designed, particularly for combinations of targets that are structurally divergent. Here we report the systematic discovery of molecules that potently inhibit both tyrosine kinases and phosphatidylinositol-3-OH kinases, two protein families that are among the most intensely pursued cancer drug targets. Through iterative chemical synthesis, X-ray crystallography and kinome-level biochemical profiling, we identified compounds that inhibit a spectrum of new target combinations in these two families. Crystal structures revealed that the dual selectivity of these molecules is controlled by a hydrophobic pocket conserved in both enzyme classes and accessible through a rotatable bond in the drug skeleton. We show that one compound, PP121, blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kinases and phosphatidylinositol-3-OH kinases. These molecules demonstrate the feasibility of accessing a chemical space that intersects two families of oncogenes.

  • Compound

    3-(4-(4-morpholinyl)pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-2- yl)phenol

  • Compound

    (9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one

  • Compound

    3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one

  • Compound

    (1R,6bR,9aS,11R,11bR)-1-(methoxymethyl)-9a,11b-dimethyl-3,6,9-trioxo-1,6,6b,7,8,9,9a,10,11,11b- decahydro-3H-furo[4,3,2-de]indeno[4,5-h]isochromen-11-yl acetate

  • Compound

    2-(4-(8-(2-(pyridin-3-yl)ethynyl)-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)acetonitrile

  • Compound

    1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol

  • Compound

    1-methyl-3-(naphthalen-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-tert-butyl-3-p-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-bromophenol

  • Compound

    2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide

  • Compound

    N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

  • Compound

    2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol

  • Compound

    1-cyclopentyl-3-(H-imidazo[1,2-a]pyridin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one

  • Compound

    tert-butyl 4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenylcarbamate

  • Compound

    4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

  • Compound

    6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine

  • Compound

    2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one

  • Compound

    N-(7,8-Dimethoxy-2,3-dihydro-imidazo[1,2-c]quinazolin-5-yl)-nicotinamide

  • Compound

    1-isopropyl-3-(quinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide

  • Compound

    2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile

  • Compound

    3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4,5-dihydrothiazol-2-yl)benzamide

  • Compound

    1-(4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)ethanone

  • Compound

    N-(4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenyl)acetamide

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-methylthiophene-2-carbaldehyde

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)furan-3-carbaldehyde

  • Compound

    N-[3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-phenyl]-methanesulfonamide

  • Compound

    3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzonitrile

  • Compound

    N-[4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-phenyl]-methanesulfonamide

  • Compound

    3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-benzenesulfonamide

  • Compound

    2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[b]thiophene-5-carbaldehyde

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-3-carbaldehyde

  • Compound

    3-(benzo[c][1,2,5]oxadiazol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    2-(4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)acetonitrile

  • Compound

    2-(3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)acetonitrile

  • Compound

    1-isopropyl-3-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(pyrimidin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-(3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)ethanone

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-methylphenol

  • Compound

    3-(4-fluoro-3-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(2,5-difluoro-4-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(2,3-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(2,4-dimethoxypyrimidin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    3-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    1-cyclopentyl-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-amino-3-methoxyphenyl)-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(3-bromo-5-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    tert-butyl 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-1-carboxylate

  • Compound

    3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-bromophenol

  • Compound

    tert-butyl 5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-1-carboxylate

  • Compound

    3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(1H-indol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(1H-indol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2,5-difluorophenol

  • Compound

    3-(1H-indol-5-yl)-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(2,3-dihydrobenzofuran-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(benzofuran-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(benzofuran-5-yl)-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-ethoxyphenol

  • Compound

    2-(4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenylamino)propan-1-ol

  • Compound

    1-isopropyl-3-(quinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    4-chloro-7-methyl-5-(3-biphenyl)-7H-pyrrolo[2,3-d]pyrimidine

  • Compound

    1-isopropyl-3-(quinolin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(1H-indol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(1H-indazol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-methyl-3-(quinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(quinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(2-ethoxynaphthalen-6-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(2-methylquinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(1H-indol-6-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(quinolin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(1H-indol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-tert-butylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(3-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(3-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(isoquinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(2-chloroquinolin-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(isoquinolin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(quinoxalin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(2-methylquinolin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(2-chloroquinolin-3-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(1-methyl-1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(1-methyl-1H-indol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(1H-indazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(1H-indazol-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(pyrido[3,2-b]pyrazin-7-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-2(1H)-one

  • Compound

    6-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-2(1H)-one

  • Compound

    3-(2-(hydrazine)quinolin-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4H-chromen-4-one

  • Compound

    6-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4H-chromen-4-one

  • Compound

    tert-butyl 6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-4-ylcarbamate

  • Compound

    6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-2-amine

  • Compound

    6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinolin-4-amine

  • Compound

    6-(4-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-4H-chromen-4-one

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2,6-difluorobenzaldehyde

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorobenzonitrile

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorobenzonitrile

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorobenzaldehyde

  • Compound

    3-(3-amino-1H-indazol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-hydroxybenzonitrile

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-benzo[d]imidazol-2(3H)-one

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-hydroxybenzonitrile

  • Compound

    6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)quinazolin-4(3H)-one

  • Compound

    3-(3-amino-1H-indazol-6-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(3-amino-1H-indazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(H-imidazo[1,2-a]pyridin-7-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-(cyclopropylmethyl)-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(naphthalen-2-yl)-1-(1-phenylallyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(naphthalen-2-yl)-1-(prop-2-ynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-p-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-amino-3-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    2-amino-5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol

  • Compound

    3-m-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-o-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(2,3-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol

  • Compound

    3-(1-isopropyl-4-(methylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol

  • Compound

    2-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol

  • Compound

    3-(4-aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(3-aminophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(4-(benzyloxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

  • Compound

    3-(3-(benzyloxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(3-(2,6-dichlorobenzyloxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(3-biphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

  • Compound

    3-(4-biphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(1,2,3,4-tetrahydronaphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    4-chloro-7-methyl-5-(naphthalen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine

  • Compound

    1-ethyl-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-allyl-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-isopropyl-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-tert-butyl-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclopentyl-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-benzyl-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(naphthalen-2-yl)-1-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    2-(4-amino-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)acetamide

  • Compound

    1-isopentyl-3-(naphthalen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(benzo[d][1,3]dioxol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(benzo[b]thiophen-2-yl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

  • Compound

    3-(3-aminobenzo[d]isoxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    2-amino-5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenol

  • Compound

    3-(3-ethoxy-4-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    2-(4-amino-3-(3-ethoxy-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethanol

  • Compound

    3-(3-(benzyloxy)-4-methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methylpheno

  • Compound

    5-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methylphenol

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    5-(1-sec-butyl-4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methylphenol

  • Compound

    5-(4-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methylphenol

  • Compound

    5-(4-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    3-(4-ethoxy-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-(4-ethoxy-3-methoxyphenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(4-amino-1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    1-cyclopentyl-3-(4-ethoxy-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-allyl-3-(4-ethoxy-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    1-cyclohexyl-3-(4-ethoxy-3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(4-amino-1-((piperidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-((piperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((piperidin-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chloropheno

  • Compound

    5-(4-amino-1-((pyrrolidin-2-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-((pyrrolidin-3-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-(2-(piperidin-4-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-((5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((4-phenyloxazol-5-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((S)-pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((S)-pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((S)-pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    5-(4-amino-1-((S)-pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-(azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    5-(4-amino-1-(azetidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-(3-methylcyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-(3-methylcyclopentyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    5-(4-amino-1-((S)-tetrahydrofuran-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-((R)-tetrahydrofuran-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-((S)-tetrahydrofuran-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((R)-tetrahydrofuran-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((R)-1-aminopropan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((R)-1-aminopropan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-((S)-1-aminopropan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-((S)-1-aminopropan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-cyclobutyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    5-(4-amino-1-cyclobutyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-chlorophenol

  • Compound

    5-(4-amino-1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-fluorophenol

  • Compound

    4-(4-amino-3-(3-hydroxy-4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)butanenitrile

  • Compound

    5-(4-amino-3-(3-hydroxy-4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pentanenitrile

  • Compound

    1-tert-butyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    5-(4-amino-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-bromophenol

  • Compound

    5-(4-amino-1-cyclobutyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-bromophenol

  • Compound

    5-(4-amino-1-cyclopentyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-bromophenol

  • Compound

    (R)-3-(4-amino-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methylpropan-1-ol

  • Compound

    (S)-3-(4-amino-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-2-methylpropan-1-ol

  • Compound

    3-(4-bromo-3-(methoxymethoxy)phenyl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    3-iodo-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    4-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-benzenesulfonamide

  • Compound

    4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenol

  • Compound

    6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)naphthalen-2-ol

  • Compound

    5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)pyridine-2-carbonitrile

  • Compound

    3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-5-fluorophenol

  • Compound

    1-isopropyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  • Compound

    (3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)methanol

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

References

  1. 1.

    & Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172–187 (2005).

  2. 2.

    & Mechanisms of drug inhibition of signalling molecules. Nature 441, 457–462 (2006).

  3. 3.

    & Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430 (2006).

  4. 4.

    et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).

  5. 5.

    & Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221–1224 (2004).

  6. 6.

    et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).

  7. 7.

    & Chemically targeting the PI3K family. Biochem. Soc. Trans. 35, 245–249 (2007).

  8. 8.

    et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851–1863 (2008).

  9. 9.

    et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).

  10. 10.

    et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437–441 (2007).

  11. 11.

    et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97, 880–887 (2005).

  12. 12.

    et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012–2024 (2005).

  13. 13.

    et al. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res. 63, 8930–8938 (2003).

  14. 14.

    et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66, 7864–7869 (2006).

  15. 15.

    et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. USA 101, 3130–3135 (2004).

  16. 16.

    et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67, 7960–7965 (2007).

  17. 17.

    & Features of selective kinase inhibitors. Chem. Biol. 12, 621–637 (2005).

  18. 18.

    et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125, 733–747 (2006).

  19. 19.

    et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–132 (2008).

  20. 20.

    , & Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16, 127–136 (2006).

  21. 21.

    & Structural evolution of the protein kinase-like superfamily. PLoS Comput. Biol. 1, e49 (2005).

  22. 22.

    , , , & Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402, 313–320 (1999).

  23. 23.

    et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909–919 (2000).

  24. 24.

    et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 12, 99–107 (2005).

  25. 25.

    , , & Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. Bioorg. Med. Chem. Lett. 18, 1027–1030 (2008).

  26. 26.

    et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271, 695–701 (1996).

  27. 27.

    et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 6, 671–678 (1999).

  28. 28.

    et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3, 639–648 (1999).

  29. 29.

    , , & Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).

  30. 30.

    et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9, 469–479 (1999).

  31. 31.

    et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341–349 (2006).

  32. 32.

    et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561–573 (2005).

  33. 33.

    et al. BAY 43–9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98, 326–334 (2006).

  34. 34.

    et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 207, 1022–1028 (1995).

  35. 35.

    et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. (in the press).

  36. 36.

    et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453, 662–666 (2008).

  37. 37.

    et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8, 128–135 (2002).

  38. 38.

    et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765–767 (1982).

  39. 39.

    et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).

  40. 40.

    et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).

  41. 41.

    Cancer: mixing cocktails. Nature 449, 993–996 (2007).

  42. 42.

    et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287–290 (2007).

  43. 43.

    et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938–1942 (2000).

  44. 44.

    & Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358–364 (2006).

  45. 45.

    , , , & A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686–7689 (1995).

  46. 46.

    et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95, 12022–12027 (1998).

  47. 47.

    , , & Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318–1321 (2005).

Download references

Acknowledgements

We thank W.A. Weiss (University of California, San Francisco) for providing glioblastoma cells, W.M. Korn (University of California, San Francisco) for providing Seg1 cells, N. Shah (University of California, San Francisco) for providing BaF3 Bcr-Abl and BaF3 Bcr-Abl T315I cells, and D. Hanahan (University of California, San Francisco) for βTC3 cells. We thank P.J. Alaimo (Seattle University) for synthetic intermediates that were used to prepare several compounds, and J.L. Garrison for helpful comments on the text. This work was supported by the Sandler Program in Asthma Research and US National Institutes of Health grant AI44009. Mass spectrometry was made possible by US National Institutes of Health shared resource grants NCRR RR015804 and NCRR RR001614. B.G. has a Ramon y Cajal fellowship from the Ministerio de Educación y Ciencia in Spain and received funding from Comunidad Autonoma de Madrid-CSIC (CCG07-CSIC/GEN-2232).

Author information

Author notes

    • Beatriz Gonzalez
    •  & Zachary A Knight

    Present addresses: Instituto de Química-Física Rocasolano (CSIC), Serrano 119, 28006 Madrid, Spain (B.G.) and The Rockefeller University, 1230 York Avenue, New York, New York 10021, USA (Z.A.K.).

Affiliations

  1. Program in Chemistry and Chemical Biology, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, USA.

    • Beth Apsel
    •  & Morri E Feldman
  2. Department of Chemistry, University of California, Berkeley, Berkeley, California 94720, USA.

    • Jimmy A Blair
    •  & Kevan M Shokat
  3. MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK.

    • Beatriz Gonzalez
    •  & Roger L Williams
  4. Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, USA.

    • Tamim M Nazif
    • , Kevan M Shokat
    •  & Zachary A Knight
  5. Invitrogen Corporation, 501 Charmany Drive, Madison, Wisconsin 53719, USA.

    • Brian Aizenstein
    •  & Randy Hoffman

Authors

  1. Search for Beth Apsel in:

  2. Search for Jimmy A Blair in:

  3. Search for Beatriz Gonzalez in:

  4. Search for Tamim M Nazif in:

  5. Search for Morri E Feldman in:

  6. Search for Brian Aizenstein in:

  7. Search for Randy Hoffman in:

  8. Search for Roger L Williams in:

  9. Search for Kevan M Shokat in:

  10. Search for Zachary A Knight in:

Contributions

B. Apsel and Z.A.K. synthesized the molecules, determined their IC50 values and performed cell proliferation assays. Z.A.K. performed the western blots. B. Apsel performed flow cytometry, angiogenesis and imaging assays. B.G. and R.L.W. determined the PI(3)K cocrystal structures. B. Apsel and J.A.B. determined the Src cocrystal structures. T.M.N. performed the HUVEC blots. B. Aizenstein and R.H. performed the Invitrogen SelectScreen. M.E.F. assisted with data analysis. Z.A.K. designed the experiments and wrote the paper, with input from B. Apsel and K.M.S.

Competing interests

K.M.S., B. Apsel and Z.A.K. are joint inventors on UC Regents-owned patent applications covering these molecules, which have been licensed to Intellikine. K.M.S. and Z.A.K. hold stock in and are consultants to Intellikine. B. Aizenstein and R.H. are employees of Invitrogen Corporation.

Corresponding author

Correspondence to Kevan M Shokat.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–5, Supplementary Tables 1–3 and Supplementary Methods

Videos

  1. 1.

    Supplementary Movie 1

    Conformational changes in Src associated with PP121 binding.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nchembio.117

Further reading